Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network - PARAGON B


This randomized, double blind, placebo controlled trial compared 30 day outcomes between patients treated with the GP IIb/IIIa inhibitor lamifiban plus standard therapy compared to standard therapy alone in the setting of ACS without persistent ST elevation.